Despite demonstrating the ability of leukemia cells carrying the PLZF::RARα fusion to fully differentiate with both ex vivo and in vivo ATRA treatment, the clinical reality is that APL with this rare fusion is commonly considered ATRA-insensitive and is linked to an unfavorable prognosis (10–12, 55). This evidence concerns the gene ZBTB16 and leukemia.